Chronic Kidney Disease Drugs Market Expected to Grow at a CAGR of 4.5% by 2027

Research Nester released a report titled “Chronic Kidney Disease Drugs Market: Global Demand Analysis & Opportunity Outlook 2027” which delivers detailed overview of the global chronic kidney disease drugs market in terms of market segmentation by drugs and by region.

Further, for the in-depth analysis, the report encompasses the industry growth drivers, restraints, supply and demand risk, market attractiveness, BPS analysis and Porter’s five force model.

The market for chronic kidney disease drugs is estimated to grow at a CAGR of about 4.5% during the forecast period, i.e., 2019-2027. The market is segmented by drug and by region, out of which, the drug segment is further segmented into antihypertensive agents, erythropoiesis-stimulating agents (EPAs), diuretics and others. Based on these, the antihypertensive agents segment is predicted to observe the highest growth over the forecast period on account of a greater demand for these drugs. Antihypertensive agents are used for lowering the blood pressure, which is a symptom of chronic kidney disease, therefore, these drugs help to control these symptoms and treat the condition.

The largest share in chronic kidney disease drugs market is estimated to be held by the market in North America on account of growing research and development activities and the presence of a large number of manufacturers in the industry. On the other hand, the market in Asia Pacific is estimated to grow at the highest rate during the forecast period as a result of increasing patient population with kidney disorders in the region and rising awareness about these renal disorders among them.

Download Sample of This Strategic Report

Rising Incidences of Chronic Kidney Disorder to Support the Market Growth

According to a report published by the Centers for Disease Control and Prevention in 2019, , around 15% of adults living in the United States, which means about 37 million people, are estimated to have chronic kidney disease (CKD). Out of these, the current estimates suggest that the disease is not diagnosed in 9 in every 10 people living with CKD. Moreover, according to the current estimates, the prevalence of CKD is higher among the older population, i.e., people who are aged 65 years or more with 38% prevalence. The growing cases of this disorder, especially among the elderly, is anticipated to become a major growth driving factor for the market over the forecast period. However, the rising competition among various chronic kidney disease drugs available in the market is anticipated to become a major limiting factor for the market growth.

This report also provides the existing competitive scenario of some of the key players of the global chronic kidney disease drugs market which includes company profiling of AstraZeneca (LON: AZN), Amgen Inc. (NASDAQ: AMGN), Pfizer Inc. (NYSE: PFE), F. Hoffmann-La Roche (SWX: ROG), GlaxoSmithKline plc. (LON: GSK), FibroGen, Inc. (NASDAQ: FGEN), Johnson & Johnson Services, Inc., Teva Pharmaceutical Industries Ltd. (TLV: TEVA), AbbVie Inc. (NYSE: ABBV) and Akebia Therapeutics, Inc. The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global chronic kidney disease drugs market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.